share_log

Mesoblast Analyst Ratings

Mesoblast Analyst Ratings

Mesoblast 分析師評級
Benzinga ·  2023/09/21 20:56
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/21/2023 1197.71% Cantor Fitzgerald → $17 Reiterates Overweight → Overweight
08/31/2023 Jefferies Upgrades Hold → Buy
08/31/2023 1197.71% Cantor Fitzgerald $23 → $17 Maintains Overweight
08/07/2023 Maxim Group Downgrades Buy → Hold
08/04/2023 William Blair Downgrades Outperform → Market Perform
08/04/2023 52.67% Piper Sandler $7 → $2 Downgrades Overweight → Neutral
08/04/2023 14.5% Chardan Capital $2 → $1.5 Maintains Sell
05/30/2023 52.67% Chardan Capital $2.5 → $2 Maintains Sell
03/01/2023 90.84% Chardan Capital → $2.5 Reiterates → Sell
02/01/2023 1655.73% Cantor Fitzgerald → $23 Reiterates → Overweight
12/06/2022 Jefferies Downgrades Buy → Hold
09/06/2022 434.35% Piper Sandler → $7 Initiates Coverage On → Overweight
06/03/2022 90.84% Chardan Capital $6.5 → $2.5 Maintains Sell
08/31/2021 396.18% Chardan Capital $7.5 → $6.5 Maintains Sell
04/07/2021 Maxim Group Upgrades Hold → Buy
01/19/2021 Jefferies Downgrades Buy → Hold
12/22/2020 Maxim Group Downgrades Buy → Hold
12/04/2020 472.52% Chardan Capital $5.5 → $7.5 Downgrades Neutral → Sell
11/20/2020 1426.72% HC Wainwright & Co. $19 → $20 Maintains Buy
10/22/2020 816.03% RBC Capital → $12 Initiates Coverage On → Sector Perform
10/02/2020 1350.38% HC Wainwright & Co. $21 → $19 Maintains Buy
05/28/2020 1503.05% HC Wainwright & Co. $14 → $21 Reiterates → Buy
10/22/2019 1655.73% Cantor Fitzgerald → $23 Assumes → Overweight
01/31/2019 396.18% HC Wainwright & Co. → $6.5 Assumes → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
2023年09月21日 1197.71% 康託·菲茨傑拉德 →$17 重申 超重→超重
2023年08月31日 - 傑富瑞 升級 持有→購買
2023年08月31日 1197.71% 康託·菲茨傑拉德 $23→$17 維護 超重
08/07/2023 - Maxim集團 評級下調 購買→Hold
08/04/2023 - 威廉·布萊爾 評級下調 跑贏→市場表現
08/04/2023 52.67% 派珀·桑德勒 $7→$2 評級下調 超重→中性
08/04/2023 14.5% 查爾丹資本 $2→$1.5 維護
2023年05月30日 52.67% 查爾丹資本 $2.5→$2 維護
03/01/2023 90.84% 查爾丹資本 →$2.5 重申 →銷售
02/01/2023 1655.73% 康託·菲茨傑拉德 →$23 重申 →超重
12/06/2022 - 傑富瑞 評級下調 購買→Hold
09/06/2022 434.35% 派珀·桑德勒 →$7 開始承保 →超重
06/03/2022 90.84% 查爾丹資本 $6.5→$2.5 維護
2021/08/31 396.18% 查爾丹資本 $7.5→$6.5 維護
04/07/2021 - Maxim集團 升級 持有→購買
2021/01/19 - 傑富瑞 評級下調 購買→Hold
12/22/2020 - Maxim集團 評級下調 購買→Hold
12/04/2020 472.52% 查爾丹資本 $5.5→$7.5 評級下調 中性→銷售
11/20/2020 1426.72% HC Wainwright公司 $19→$20 維護
10/22/2020 816.03% 加拿大皇家銀行資本 →$12 開始承保 →行業表現
10/02/2020 1350.38% HC Wainwright公司 $21→$19 維護
05/28/2020 1503.05% HC Wainwright公司 $14→$21 重申 →購買
2019年10月22日 1655.73% 康託·菲茨傑拉德 →$23 假設 →超重
2019年01月31日 396.18% HC Wainwright公司 →$6.5 假設 →購買

What is the target price for Mesoblast (MESO)?

中胚層(Meso)的目標價是多少?

The latest price target for Mesoblast (NASDAQ: MESO) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $17.00 expecting MESO to rise to within 12 months (a possible 1197.71% upside). 11 analyst firms have reported ratings in the last year.

坎託·菲茨傑拉德於2023年9月21日報道了中胚層(納斯達克:MESO)的最新目標價。這家分析公司將目標價定為17美元,預計Meso將在12個月內上漲(可能上漲1197.71%)。過去一年,有11家分析公司公佈了評級。

What is the most recent analyst rating for Mesoblast (MESO)?

分析師對中胚層(Meso)的最新評級是什麼?

The latest analyst rating for Mesoblast (NASDAQ: MESO) was provided by Cantor Fitzgerald, and Mesoblast reiterated their overweight rating.

中原地產(納斯達克股票代碼:MESO)的最新分析師評級由康託·菲茨傑拉德提供,中原地產重申其增持評級。

When is the next analyst rating going to be posted or updated for Mesoblast (MESO)?

中胚層(MESO)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mesoblast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mesoblast was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Mesoblast的高管和客戶交談,以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。中胚層的最後一次評級是在2023年9月21日提交的,所以你應該預計下一次評級將在2024年9月21日左右的某個時候提供。

Is the Analyst Rating Mesoblast (MESO) correct?

分析師對中胚層細胞(Meso)的評級正確嗎?

While ratings are subjective and will change, the latest Mesoblast (MESO) rating was a reiterated with a price target of $0.00 to $17.00. The current price Mesoblast (MESO) is trading at is $1.31, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的中胚層(Meso)評級被重申,目標價在0.00美元至17.00美元之間。中成纖維(Meso)目前的交易價格為1.31美元,在分析師的預測範圍內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論